The stock of Alumis Inc (NASDAQ: ALMS) has increased by 13.38 when compared to last closing price of 3.78.Despite this, the company has seen a loss of -4.46% in its stock price over the last five trading days. globenewswire.com reported 2025-03-25 that – Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales -Deal underscores the commercial potential of Alumis’ ESK-001 and leverages Kaken’s regional capabilities and expertise in novel dermatology treatments -Kaken has the option to license ESK-001 for further clinical development and commercialization in rheumatological and gastrointestinal diseases SOUTH SAN FRANCISCO, Calif. and BUNKYO-KU, Tokyo, March 25, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and Kaken Pharmaceutical Co., Ltd.
Is It Worth Investing in Alumis Inc (NASDAQ: ALMS) Right Now?
Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ALMS is 25.25M, and currently, shorts hold a 11.63% of that float. The average trading volume for ALMS on March 25, 2025 was 207.03K shares.
ALMS’s Market Performance
ALMS’s stock has seen a -4.46% decrease for the week, with a -18.32% drop in the past month and a -50.41% fall in the past quarter. The volatility ratio for the week is 15.78%, and the volatility levels for the past 30 days are at 10.77% for Alumis Inc The simple moving average for the past 20 days is -4.97% for ALMS’s stock, with a -54.98% simple moving average for the past 200 days.
Analysts’ Opinion of ALMS
Many brokerage firms have already submitted their reports for ALMS stocks, with Oppenheimer repeating the rating for ALMS by listing it as a “Outperform.” The predicted price for ALMS in the upcoming period, according to Oppenheimer is $32 based on the research report published on January 30, 2025 of the current year 2025.
Robert W. Baird, on the other hand, stated in their research note that they expect to see ALMS reach a price target of $25. The rating they have provided for ALMS stocks is “Outperform” according to the report published on October 31st, 2024.
H.C. Wainwright gave a rating of “Buy” to ALMS, setting the target price at $30 in the report published on October 17th of the previous year.
ALMS Trading at -23.50% from the 50-Day Moving Average
After a stumble in the market that brought ALMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.37% of loss for the given period.
Volatility was left at 10.77%, however, over the last 30 days, the volatility rate increased by 15.78%, as shares sank -10.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.78% lower at present.
During the last 5 trading sessions, ALMS fell by -2.77%, in comparison to the 20-day moving average, which settled at $4.51. In addition, Alumis Inc saw -45.55% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALMS starting from Foresite Labs, LLC, who purchase 2,500,000 shares at the price of $16.00 back on Jul 01 ’24. After this action, Foresite Labs, LLC now owns 5,584,889 shares of Alumis Inc, valued at $40,000,000 using the latest closing price.
Foresite Capital Management V, the 10% Owner of Alumis Inc, purchase 2,500,000 shares at $16.00 during a trade that took place back on Jul 01 ’24, which means that Foresite Capital Management V, is holding 5,584,889 shares at $40,000,000 based on the most recent closing price.
Stock Fundamentals for ALMS
The total capital return value is set at -1.04. Equity return is now at value -198.66, with -136.66 for asset returns.
Based on Alumis Inc (ALMS), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -8.3.
Currently, EBITDA for the company is -297.6 million with net debt to EBITDA at 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.01.
Conclusion
In conclusion, Alumis Inc (ALMS) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
